Edition:
United Kingdom

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

2.34USD
16 Jan 2019
Change (% chg)

$0.67 (+40.12%)
Prev Close
$1.67
Open
$1.65
Day's High
$3.71
Day's Low
$1.65
Volume
4,464,585
Avg. Vol
123,105
52-wk High
$22.05
52-wk Low
$0.66

Chart for

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: 3.04
Market Cap(Mil.): $39.03
Shares Outstanding(Mil.): 30.25
Dividend: --
Yield (%): --

Financials

  BIOC.OQ Industry Sector
P/E (TTM): -- 32.17 34.38
EPS (TTM): -1.26 -- --
ROI: -328.01 13.75 14.96
ROE: -550.52 16.50 16.53

BRIEF-Biocept And Prognos Enter Into Partnership

* BIOCEPT AND PROGNOS ENTER INTO PARTNERSHIP TO APPLY ARTIFICIAL INTELLIGENCE IN ORDER TO HELP PHARMACEUTICAL AND LIFE SCIENCES COMPANIES OPTIMIZE COMMERCIALIZATION OF BIOMARKER-TARGETED THERAPIES IN ONCOLOGY Source text for Eikon: Further company coverage:

18 Dec 2018

Earnings vs. Estimates